| Literature DB >> 26498595 |
Ademola O Olaniran1, Sphephile B T Nzimande2, Ndumiso G Mkize3.
Abstract
BACKGROUND: Treated wastewater effluent has been found to contain high levels of contaminants, including disease-causing bacteria such as Listeria and Aeromonas species. The aim of this study was to evaluate the antimicrobial resistance and virulence signatures of Listeria and Aeromonas spp. recovered from treated effluents of two wastewater treatment plants and receiving rivers in Durban, South Africa.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26498595 PMCID: PMC4619433 DOI: 10.1186/s12866-015-0570-x
Source DB: PubMed Journal: BMC Microbiol ISSN: 1471-2180 Impact factor: 3.605
Characteristics of primers used for PCR amplification of genus specific genes and virulence genes
| Organism | Primer | Sequence (5′–3′) | Product size (bp) | References |
|---|---|---|---|---|
|
| Plc A | CTG CTT GAG CGT TCA TGT CTC ATC CCC C | 1484 | [ |
| ATG GGT TTC ACT CTC CTT CTA C | ||||
| Act A | CGC CGC GGA AAT TAA AAA AAG A | 839 | ||
| ACG AAG GAA CCG GGC TGC TAG | ||||
| Iap | ACA AGC TGC ACC TGT TGC AG | 131 | ||
| TGA CAG CGT GTG TAG TAG CA | ||||
|
| aer-F | CCTATGGCCTGAGCGAGAAG | 431 | [ |
| aer-R | CCAGTTCCAGTCCCACCACT | |||
| lip-F | CA(C/T)CTGGT(T/G)CCGCTCAAG | 247 | ||
| lip-R | GT(A/G)CCGAACCAGTCGGAGAA | |||
|
| List-Universal 1 | ATGTCATGGAATAA | 457–610 | [ |
| List-Universal 2 | GCTTTTCCAAGGTGTTTTT | |||
|
| gyrB3F | TCCGGCGGTCTGCACGGCGT | 1100 | [ |
| gyrB14R | TTGTCCGGGTTGTACTCGTC |
Antimicrobial resistance/susceptibility profile of Aeromonas and Listeria species isolates
| Antibiotic class | Antibiotics | Conc (μg) | Bacterial isolates | |||||
|---|---|---|---|---|---|---|---|---|
|
|
| |||||||
| n (Resistant) | n (Susceptible) | n (Intermediate) | n (Resistant) | n (Susceptible) | n (Intermediate) | |||
| β-Lactams | Penicillin (P) | 10 (10) | 100 (100) | 0 (0) | 0 (0) | 78 (100) | 0 (0) | 0 (0) |
| Cephalothin (KF) | 30 | 82 (82) | 15 (15) | 3 (3) | 47 (60.26) | 24 (30.77) | 7 (8.97) | |
| Aminoglycosides | Gentamicin (CN) | 10 | 0 (0) | 100 (100) | 0 (0) | 0 | 72 (92.31) | 6 (7.69) |
| Kanamycin (K) | 5 | 14 (14) | 59 (59) | 27 (27) | 41 (52.56) | 18 (23.08) | 19 (24.36) | |
| Amikacin (AK) | 30 | 0 (0) | 95 (95) | 5 (5) | 0 | 78 (100) | 0 | |
| Carbapenems | Ertapenem (ETP) | 10 | 23 (23) | 72 (72) | 5 (5) | 22 (28.21) | 48 (61.54) | 8 (10.25) |
| Meropenem (MEM) | 10 | 11 (11) | 79 (79) | 10 (10) | 0 (0) | 70 (89.74) | 8 (10.26) | |
| Cephalosporin | Cefotaxime (CTX) | 30 | 6 (6) | 82 (82) | 12 (12) | 24 (30.77) | 39 (50) | 15 (19.23) |
| Ceftriaxone (CRO) | 30 | 22 (22) | 78 (78) | 0 (0) | 19 (24.36) | 45 (59.69) | 14 (17.95) | |
| Glycopeptides | Vancomycin (VA) | 30 | 100 (100) | 0 (0) | 0 (0) | 24 (30.77) | 54 (69.23) | 0 (0) |
| Lincosamides | Clindamycin (DA) | 10 | 100 (100) | 0 (0) | 0 (0) | 9 (11.54) | 69 (88.46) | 0 (0) |
| Macrolides | Erythromycin (E) | 15 | 58 (58) | 11 (11) | 31 (31) | 78 (100) | 0 (0) | 0 (0) |
| Nitrofurans | Nitrofurantoin (F) | 50 | 4 (4) | 72 (72) | 24 (24) | 50 (64.10) | 6 (7.69) | 22 (28.20) |
| Penicillins | Ampicillin (AMP) | 10 | 100 (100) | 0 (0) | 0 (0) | 65 (83.33) | 8 (10.26) | 5 (6.41) |
| Polypeptides | Colistin (CT) | 10 | 14 (14) | 86 (86) | 0 (0) | 16 (20.51) | 62 (79.48) | 0 (0) |
| Quinolones | Nalidixic acid (NA) | 30 | 56 (56) | 44 (44) | 0 (0) | 78 (100) | 0 (0) | 0 (0) |
| Mixofloxacin (MXF) | 5 | 3 (3) | 83 (83) | 14 (14) | 3 (3.85) | 72 (92.30) | 3 (3.85) | |
| Ciprofloxacin (CIP) | 5 | 0 (0) | 94 (94) | 6 (6) | 0 | 75 (96.15) | 3 (3.85) | |
| Sulfonamides | Trimethoprim (W) | 5 | 56 (56) | 38 (38) | 6 (6) | 53 (67.95) | 20 (25.64) | 5 (6.41) |
| Tetracyclines | Tetracycline (TE) | 10 | 19 (19) | 44 (44) | 37 (37) | 37 (47.44) | 31 (39.74) | 10 (12.82) |
| Other | Streptomycin (S) | 25 | 16 (16) | 70 (70) | 14 (14) | 0 | 78 (100) | 0 |
| Chloramphenicol (C) | 30 | 4 (4) | 95 (95) | 1 (1) | 0 | 78 (100) | 0 | |
| Fosfomycin (FOS) | 50 | 3 (3) | 88 (88) | 9 (9) | 0 | 78 (100) | 0 | |
| Fusidic Acid (FD) | 10 | 100 (100) | 0 (0) | 0 (0) | 0 | 78 (100) | 0 | |
Fig. 1a. Agarose gel showing PCR amplicons of the gyrB gene of representative Aeromonas spp. isolates (lanes 2–17), M: 100 pb molecular marker and lane 1: negative control. b. Agarose gel showing PCR amplicons of the iap gene of representative Listeria spp. isolates (lanes 2–9), M: molecular marker and lane 1: negative control
Fig. 2Multidrug resistance patterns in (a) Listeria spp. and (b) Aeromonas spp. indicating the percentage isolates resistant to different number of antibiotic classes
Fig. 3a. Agarose gel showing PCR amplicons of three virulence associated genes (plcA, actA, and iap) detected in representative Listeria spp. (lanes 1 & 3) and L. monocytogenes (ATCC 19115) (Lane 2). M: DNA marker (100 to 3000 bp) and Lane 4: negative control. b. Agarose gel showing PCR amplicons of the Aerolysin (aer) virulence associated gene of representative Aeromonas spp., M: DNA marker (100 bp), lane 1–7: amplified PCR products, Lane 8: negative control. c. Agarose gel showing PCR amplicons of the Lipase (lip) virulence associated gene of representative Aeromonas spp., M: DNA marker (100 bp), lane 1–17: amplified PCR products